LIBTAYO may help
shrink tumors.
LIBTAYO was studied in a clinical
trial which included patients with
advanced BCC after they
were treated with an HHI.
In the trial, 27 out of 84 patients (32%) saw an improvement in their locally advanced BCC with LIBTAYO.
These patients had responses that lasted between 2.1 months and 36.8+ months. 13 out of 54 patients (24%) saw an improvement in their metastatic BCC with LIBTAYO. These patients had responses that lasted between 4.8 months and 25.8+ months. Plus sign [+] means this patient was still responding to treatment at their last assessment.
Support for eligible patients taking LIBTAYO, including information on financial assistance programs and access to Surround Support.

Find out more about treatment with LIBTAYO.
Download
brochure
brochure
What is advanced BCC?
Learn more about how BCC can progress to advanced disease.